Antibacterial performance of MELITININ - BMAP27 hybrid peptide against Staphylococcus aureus and Pseudomonas aeruginosa strains

Multiple drug-resistant (MDR) bacterial strains have spread in different parts of hospitals. The aim of this study was to design and synthesize an effective hybrid peptide by combining different parts of two peptides to achieve the highest antibacterial activity and its inhibitory effect against Staphylococcus aureus and Pseudomonas aeruginosa strains.

From two antimicrobial peptides MELITININ + BMAP27, a hybrid peptide of the both peptides was considered and synthesized. The antibacterial effect of this peptide on Staphylococcus aureus and Pseudomonas aeruginosa strains was determined.

P. aeruginosa exhibited a growth inhibition zone with a diameter of 15 mm and S. aureus by creating a growth inhibition zone of 16 mm in diameter. Further, at 0.5% peptide concentration, P. aeruginosa exhibited a growth inhibition zone with a diameter of 19 mm and S. aureus outlined a growth inhibition zone with a diameter of 20 mm against peptide. clinical strains from both bacterial species demonstrated higher resistance rates to antibiotics and peptides. In some concentrations, the combination of peptides and antibiotics increased the susceptibility of bacterial species but was not significant in all concentrations.

A hybrid peptide consisting of two peptides, melitinin and BMAP-27, has antibacterial effect on clinical and standard strains of Staphylococcus aureus and Pseudomonas aeruginosa. The combination of this peptide with antibiotics can be effective in reducing side effects and antibiotic resistance.